Evaluation of New Markers to Assess Kidney Function

You may not qualify if:

• Currently undergoing or having received peritoneal dialysis or hemodialysis treatment within the past three months. Subjects with an eGFR \< 30 mL/min/1.73 m2 will not receive Magnevist during the study visit.
• Active pulmonary edema.
• Class III or IV congestive heart failure.
• History of urinary retention or current urinary incontinence.
• Inability to cease taking medications that affect creatinine levels (e.g., bactrim, cimetidine) for one week prior to the study visit.
• Inability to maintain a stable regimen of anti-inflammatory agents and angiotensin converting enzyme inhibitors for one week prior to study visit
• Current treatment with amiodarone or metformin.
• Acute exacerbation of asthma or chronic obstructive lung disease in the past three months requiring hospitalization or oral steroid therapy.
• Inadequate venous access.
• End stage conditions such as cirrhosis.
• Active treatment for cancer.
• Progressive neurological diseases.
• Severe gastric immotility.
• Recent radiation exposure to γ-emitting isotope other than technetium
• Known allergy to any of the GFR markers, iodine, or shellfish. Subjects who are not sure if they have an iodine allergy because they have not eaten shellfish or have never received contrast dye will be excluded from participation.
• +9 more criteria